TP53 and B-cell chronic lymphocytic leukemia: WES of CLL at the time of venetoclax resistance revealed mutations in other cancer-related genes, including BRAF, BTG1, CDKN2A/B, CD274, NOTCH1, RB1, SF3B1, and TP53 [136,137].